Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia.
² Department of Medicine, Columbia University Irving Medical Center, New York, New York.
³ Division of Pulmonary and Critical Care Medicine, and.
⁴ Department of Medicine, The University of Chicago Medicine, Chicago, Illinois.
⁵ Department of Radiology, National Jewish Health, Denver, Colorado.
⁶ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
⁷ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
⁸ Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.
⁹ Department of Radiology, and.
¹⁰ Interstitial Lung Disease Service, Royal Brompton Hospital, London, United Kingdom.
¹¹ National Heart and Lung Institute, Imperial College, London, United Kingdom.
¹² Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas.
¹³ Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and.
¹⁴ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York.

John S Kim et al. Ann Am Thorac Soc. 2023 Dec.

. 2023 Dec;20(12):1683-1693.

doi: 10.1513/AnnalsATS.202303-188PS.

¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia.
² Department of Medicine, Columbia University Irving Medical Center, New York, New York.
³ Division of Pulmonary and Critical Care Medicine, and.
⁴ Department of Medicine, The University of Chicago Medicine, Chicago, Illinois.
⁵ Department of Radiology, National Jewish Health, Denver, Colorado.
⁶ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
⁷ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
⁸ Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Rome, Italy.
⁹ Department of Radiology, and.
¹⁰ Interstitial Lung Disease Service, Royal Brompton Hospital, London, United Kingdom.
¹¹ National Heart and Lung Institute, Imperial College, London, United Kingdom.
¹² Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas.
¹³ Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and.
¹⁴ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York.

No abstract available

Figures

1. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med . 2020;383:958–968. - PubMed
1. Hewson T, McKeever TM, Gibson JE, Navaratnam V, Hubbard RB, Hutchinson JP. Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax . 2017 doi: 10.1136/thoraxjnl-2017-210177. - DOI - PubMed
1. King TE, Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. ASCEND Study Group A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med . 2014;370:2083–2092. - PubMed
1. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. INPULSIS Trial Investigators Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med . 2014;370:2071–2082. - PubMed
1. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. INBUILD Trial Investigators Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med . 2019;381:1718–1727. - PubMed